RIP1 kinase activity is dispensable for normal development but is a key regulator of inflammation in SHARPIN-deficient mice

od Berger, Scott B., Kasparcova, Viera, Hoffman, Sandy, Swift, Barb, Dare, Lauren, Schaeffer, Michelle, Capriotti, Carol, Cook, Michael, Finger, Joshua, Hughes-Earle, Angela, Harris, Philip A., Kaiser, William J., Mocarski, Edward S., Bertin, John, Gough, Peter J.
Wydane 2014

Extended pharmacodynamic responses observed upon PROTAC-mediated degradation of RIPK2

od Mares, Alina, Miah, Afjal H., Smith, Ian E. D., Rackham, Mark, Thawani, Aditya R., Cryan, Jenni, Haile, Pamela A., Votta, Bartholomew J., Beal, Allison M., Capriotti, Carol, Reilly, Michael A., Fisher, Don T., Zinn, Nico, Bantscheff, Marcus, MacDonald, Thomas T., Vossenkamper, Anna, Dace, Phoebe, Churcher, Ian, Benowitz, Andrew B., Watt, Gillian, Denyer, Jane, Scott-Stevens, Paul, Harling, John D.
Wydane w Commun Biol (2020)

Caspase-8 Collaborates with Caspase-11 to Drive Tissue Damage and Execution of Endotoxic Shock

od Mandal, Pratyusha, Feng, Yanjun, Lyons, John D., Berger, Scott B., Otani, Shunsuke, DeLaney, Alexandra, Tharp, Gregory K., Maner-Smith, Kristal, Burd, Eileen M., Schaeffer, Michelle, Hoffman, Sandra, Capriotti, Carol, Roback, Linda, Young, Cedrick B., Liang, Zhe, Ortlund, Eric A., DiPaolo, Nelson C., Bosinger, Steven, Bertin, John, Gough, Peter J., Brodsky, Igor E., Coopersmith, Craig M., Shayakhmetov, Dmitry M., Mocarski, Edward S.
Wydane w Immunity (2018)

Discovery of Small Molecule RIP1 Kinase Inhibitors for the Treatment of Pathologies Associated with Necroptosis

od Harris, Philip A., Bandyopadhyay, Deepak, Berger, Scott B., Campobasso, Nino, Capriotti, Carol A., Cox, Julie A., Dare, Lauren, Finger, Joshua N., Hoffman, Sandra J., Kahler, Kirsten M., Lehr, Ruth, Lich, John D., Nagilla, Rakesh, Nolte, Robert T., Ouellette, Michael T., Pao, Christina S., Schaeffer, Michelle C., Smallwood, Angela, Sun, Helen H., Swift, Barbara A., Totoritis, Rachel D., Ward, Paris, Marquis, Robert W., Bertin, John, Gough, Peter J.
Wydane 2013

Identification of Quinoline-Based RIP2 Kinase Inhibitors with an Improved Therapeutic Index to the hERG Ion Channel

od Haile, Pamela A., Casillas, Linda N., Bury, Michael J., Mehlmann, John F., Singhaus, Robert, Charnley, Adam K., Hughes, Terry V., DeMartino, Michael P., Wang, Gren Z., Romano, Joseph J., Dong, Xiaoyang, Plotnikov, Nikolay V., Lakdawala, Ami S., Convery, Maire A., Votta, Bartholomew J., Lipshutz, David B., Desai, Biva M., Swift, Barbara, Capriotti, Carol A., Berger, Scott B., Mahajan, Mukesh K., Reilly, Michael A., Rivera, Elizabeth J., Sun, Helen H., Nagilla, Rakesh, LePage, Carol, Ouellette, Michael T., Totoritis, Rachel D., Donovan, Brian T., Brown, Barry S., Chaudhary, Khuram W., Gough, Peter J., Bertin, John, Marquis, Robert W.
Wydane w ACS Med Chem Lett (2018)

Correction to Identification of Quinoline-Based RIP2 Kinase Inhibitors with an Improved Therapeutic Index to the hERG Ion Channel

od Haile, Pamela A., Casillas, Linda N., Bury, Michael J., Mehlmann, John F., Singhaus, Robert, Charnley, Adam K., Hughes, Terry V., DeMartino, Michael P., Wang, Gren Z., Romano, Joseph J., Dong, Xiaoyang, Plotnikov, Nikolay V., Lakdawala, Ami S., Duraiswami, Chaya, Convery, Maire A., Votta, Bartholomew J., Lipshutz, David B., Desai, Biva M., Swift, Barbara, Capriotti, Carol A., Berger, Scott B., Mahajan, Mukesh K., Reilly, Michael A., Rivera, Elizabeth J., Sun, Helen H., Nagilla, Rakesh, LePage, Carol, Ouellette, Michael T., Totoritis, Rachel D., Donovan, Brian T., Brown, Barry S., Chaudhary, Khuram W., Gough, Peter J., Bertin, John, Marquis, Robert W.
Wydane w ACS Med Chem Lett (2020)